Metastatic Clinical Trials in Shenzhen, Guangdong
19 recruitingShenzhen, Guangdong, China
Showing 1–19 of 19 trials
Recruiting
Phase 2Phase 3
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Metastatic Pancreatic Ductal AdenocarcinomaCachexia
Pfizer982 enrolled114 locationsNCT06989437
Recruiting
Phase 1Phase 2
Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Beijing Biotech36 enrolled1 locationNCT07551349
Recruiting
Phase 2Phase 3
A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb590 enrolled264 locationsNCT07063745
Recruiting
Phase 1Phase 2
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
MetastaticAdvanced Unresectable
Beijing Biotech72 enrolled1 locationNCT07523529
Recruiting
Phase 1Phase 2
PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors
Advanced or Metastatic Solid Tumors
Beijing Biotech60 enrolled1 locationNCT07510828
Recruiting
Phase 1Phase 2
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
HER2-positive Breast CancerBreast Cancer (Advanced/Metastatic)
Beijing Biotech60 enrolled1 locationNCT07510802
Recruiting
Phase 1Phase 2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Metastatic Solid TumorsLocally Advanced Solid Tumors
Turning Point Therapeutics, Inc.500 enrolled165 locationsNCT03093116
Recruiting
Phase 1Phase 2
Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
Metastatic Liver CancerAdvanced Hepatocellular Carcinoma (HCC)
Beijing Biotech30 enrolled1 locationNCT07500220
Recruiting
Phase 1
Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Urothelial Carcinoma+2 more
Beijing Biotech42 enrolled1 locationNCT07492628
Recruiting
Phase 1Phase 2
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
HER2-positive Breast CancerBreast Cancer (Locally Advanced or Metastatic)
Beijing Biotech60 enrolled1 locationNCT07486089
Recruiting
Phase 1Phase 2
Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma (PDAC)Unresectable Locally Advanced or Metastatic Disease
Beijing Biotech42 enrolled1 locationNCT07480928
Recruiting
Phase 1Phase 2
Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer
Colorectal Cancer MetastaticAdenocarcinoma of Colon
Beijing Biotech48 enrolled1 locationNCT07462650
Recruiting
Early Phase 1
Universal CAR-T Cells (REVO-UWD-01) for Metastatic Colorectal Cancer
Metastatic Colorectal CancerCRC (Colorectal Cancer)
Wondercel Biotech (ShenZhen)30 enrolled2 locationsNCT06653010
Recruiting
Phase 3
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Metastatic Pancreatic Ductal Adenocarcinoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.566 enrolled70 locationsNCT07165951
Recruiting
Phase 1Phase 2
A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer
Pancreatic Cancer Metastatic
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center23 enrolled1 locationNCT07040228
Recruiting
Early Phase 1
Autologous CAR-T Cells (WD-01) for Metastatic Colorectal Cancer
Metastatic Colorectal CancerCRC (Colorectal Cancer)
Wondercel Biotech (ShenZhen)30 enrolled2 locationsNCT06675513
Recruiting
Phase 1Phase 2
Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer
Metastatic Colorectal Cancer
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center30 enrolled1 locationNCT06776757
Recruiting
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer with Different HER2 Expression Patterns
Metastatic Breast Cancer
Sun Yat-sen University800 enrolled23 locationsNCT06551220
Recruiting
Phase 3
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
Metastatic Breast Cancer
Herui Yao210 enrolled13 locationsNCT04263298